Correlation Between Joint Stock and Spyre Therapeutics

Can any of the company-specific risk be diversified away by investing in both Joint Stock and Spyre Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Joint Stock and Spyre Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Joint Stock and Spyre Therapeutics, you can compare the effects of market volatilities on Joint Stock and Spyre Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Joint Stock with a short position of Spyre Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Joint Stock and Spyre Therapeutics.

Diversification Opportunities for Joint Stock and Spyre Therapeutics

0.57

Correlation Coefficient

Joint Stock  Spyre Therapeutics

Very weak diversification

The 3 months correlation between Joint and Spyre is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding Joint Stock and Spyre Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spyre Therapeutics and Joint Stock is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Joint Stock are associated (or correlated) with Spyre Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spyre Therapeutics has no effect on the direction of Joint Stock i.e., Joint Stock and Spyre Therapeutics go up and down completely randomly.

Pair Corralation between Joint Stock and Spyre Therapeutics

Given the investment horizon of 90 days Joint Stock is expected to generate 0.6 times more return on investment than Spyre Therapeutics. However, Joint Stock is 1.66 times less risky than Spyre Therapeutics. It trades about -0.03 of its potential returns per unit of risk. Spyre Therapeutics is currently generating about -0.04 per unit of risk. If you would invest  10,454  in Joint Stock on September 25, 2024 and sell it today you would lose (672.00) from holding Joint Stock or give up 6.43% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Joint Stock  vs.  Spyre Therapeutics

Joint Stock

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Joint Stock has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Joint Stock is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders.

Spyre Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest fragile performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Pair Trading with Joint Stock and Spyre Therapeutics

The main advantage of trading using opposite Joint Stock and Spyre Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Joint Stock position performs unexpectedly, Spyre Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will offset losses from the drop in Spyre Therapeutics' long position.

The idea behind Joint Stock and Spyre Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.